Summary
LLY Chart
Can LLY's Next-Generation Obesity Pipeline Fuel Further Growth?
Eli Lilly bets on next-generation obesity candidates like orforglipron and retatrutide to sustain growth amid rising competition.
Buy Eli Lilly While The Market Hesitates And Let Time Make You Dominate
Eli Lilly is positioned for a 30-50% return in the next 12 months based on a nexus of value and growth. While others hesitate on greatness, I buy at the prices everyone else wishes they did. Risks are the price of admission to elite returns. No champion in the market rises without scar tissue.
Eli Lilly: It Is A Bet On Human Longevity
Eli Lilly's recent stock dip creates a compelling buying opportunity, with its valuation multiples falling to 2022 levels, despite explosive growth prospects and a deep, innovative product pipeline. Driven by blockbuster drugs Mounjaro and Zepbound, Lilly's revenue surged 45% YoY. Near-term PBM headwinds are manageable, given the drugs' superior clinical data and massive market demand. Beyond current successes, Lilly is innovating with a potential game-changing oral GLP-1 (orforglipron) and a visionary "one-and-done" gene therapy acquisition (Verve) targeting heart disease.
ELI LILLY Dividends
 LLY In 1 month Estimated | Quarterly | $1.5 Per Share |
| LLY 1 month ago Paid | Quarterly | $1.5 Per Share |
| LLY 4 months ago Paid | Quarterly | $1.5 Per Share |
| LLY 7 months ago Paid | Quarterly | $1.3 Per Share |
| LLY 10 months ago Paid | Quarterly | $1.3 Per Share |
| LLY 15 May 2024 Paid | Quarterly | $1.3 Per Share |
ELI LILLY Earnings
| 28 Apr 2025 Date | | - Cons. EPS | - EPS |
| 6 Feb 2025 Date | | 5.07 Cons. EPS | 5.32 EPS |
| 4 Feb 2025 Date | | - Cons. EPS | - EPS |
| 30 Oct 2024 Date | | 1.47 Cons. EPS | 1.18 EPS |
| 8 Aug 2024 Date | | 2.6 Cons. EPS | 3.92 EPS |
| LLY In 1 month Estimated | Quarterly | $1.5 Per Share |
| LLY 1 month ago Paid | Quarterly | $1.5 Per Share |
| LLY 4 months ago Paid | Quarterly | $1.5 Per Share |
| LLY 7 months ago Paid | Quarterly | $1.3 Per Share |
| LLY 10 months ago Paid | Quarterly | $1.3 Per Share |
| LLY 15 May 2024 Paid | Quarterly | $1.3 Per Share |
| 28 Apr 2025 Date | | - Cons. EPS | - EPS |
| 6 Feb 2025 Date | | 5.07 Cons. EPS | 5.32 EPS |
| 4 Feb 2025 Date | | - Cons. EPS | - EPS |
| 30 Oct 2024 Date | | 1.47 Cons. EPS | 1.18 EPS |
| 8 Aug 2024 Date | | 2.6 Cons. EPS | 3.92 EPS |
ELI LILLY (LLY) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has ELI LILLY ever had a stock split?
ELI LILLY Profile
| Drug Manufacturers - General Industry | Healthcare Sector | David A. Ricks CEO | XHAN Exchange | US5324571083 ISIN |
| US Country | 47,000 Employees | 14 Feb 2025 Last Dividend | 16 Oct 1997 Last Split | 13 Jan 1978 IPO Date |
Overview
Eli Lilly and Company is a global leader in the discovery, development, and marketing of human pharmaceuticals. With a history dating back to 1876, the company has established itself as a key player in the pharmaceutical industry, offering a wide range of products aimed at treating a variety of conditions. Headquartered in Indianapolis, Indiana, Eli Lilly and Company has forged multiple collaborations with other pharmaceutical giants such as Incyte Corporation, Boehringer Ingelheim Pharmaceuticals, Inc., F. Hoffmann-La Roche Ltd, Genentech, Inc., Biologics, Inc., AbCellera Biologics Inc., and Chugai Pharmaceutical Co., Ltd., enhancing its product offerings and research capabilities across different therapeutic areas.
Products and Services
- Diabetes Care
Includes a comprehensive portfolio of insulin and other diabetes treatments: Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500. Additionally, the company offers Jardiance, Mounjaro, and Trulicity for managing type 2 diabetes.
- Oncology
Provides a range of products for cancer treatment, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio, focusing on different types of cancer and treatment approaches.
- Immunology
Olumiant is offered for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19. Taltz is available for treating plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis.
- Digestive Diseases
Omvoh is targeted at ulcerative colitis, reflecting the company's commitment to addressing gastrointestinal disorders.
- Neurological Disorders
Includes Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain. Emgality is provided for migraine prevention and treatment of episodic cluster headache.
- Other Therapeutic Areas
The company also offers Cialis for erectile dysfunction and benign prostatic hyperplasia; Forteo for osteoporosis treatment; Zepbound for obesity management; and Ebglyss for severe atopic dermatitis, showcasing Eli Lilly's diverse portfolio catering to various health conditions.
Contact Information
